FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2249501518> ?p ?o ?g. }

• W2249501518 endingPage "13526" @default.
• W2249501518 startingPage "13526" @default.
• W2249501518 abstract "13526 Background: we began using PET in 1994 and since the beginning of 2000 we started with a PET/CT system. Aim of our study was to evaluate if PET/CT is a decision making tool in patients with a history of colon tumors. Methods: we performed PET/CT in 26 patients, 14 males and 12 females (mean age 60.9, range 42–75 years) already treated for a colon cancer. Each patient was submitted to two PET/CT scans in a period of 5–11 months. PET/CT was performed using 18F-FDG as radiopharmaceutical. In all patients other examinations were perfomed, such as liver ecography, pelvis MRI and CT scan. Results: in the first PET/CT imaging, 11/26 patients presented with normal tumor markers but suspected relapse on the basis of CI, 7/26 had increased markers but negative CI, the other 8 patients had both CI and tumor markers meaningful for recurrence. 7/26 PET/CT were normal: 5 cases with negative tumor markers but positive CI and 2 patients with increased CEA levels. Among the 19/26 positive PET/CT scans, 7 patients had normal marker levels. All positive PET/CT patients were treated and, at the second examination, progressive disease was evident in 11 out of 19. For the 7 previous negative PET/CT, the second findings showed tumor recurrence in 2 patients, but PET/CT became negative in 5 previously positive cases, submitted to surgery and/or chemotherapy. This method detected relapse in 73% of the patients and, during the follow up, it was sensitive to identify progressive disease or to prove treatment’colon cancer, based on tumoral marker assays and CI, is poorly sensitive to detect relapse. Our PET/CT data show that 37% of cases with normal marker levels have a recurrent disease. The overall results of our preliminary data lead to further considerations: 1) PET/CT gives a precise localization of lung or nodal metastases and local relapse; 2) the repeated PET/CT scan is reliable also to evaluate the effect of therapies; 3) this imaging modality may be crucial to detect relapse, but more data are needed to assess the proper time to perform PET/CT in the follow up to have a real gain in life expectancy. No significant financial relationships to disclose." @default.
• W2249501518 created "2016-06-24" @default.
• W2249501518 creator A5001407205 @default.
• W2249501518 creator A5010915843 @default.
• W2249501518 creator A5011192513 @default.
• W2249501518 creator A5021044941 @default.
• W2249501518 creator A5044706204 @default.
• W2249501518 creator A5059003996 @default.
• W2249501518 creator A5060807260 @default.
• W2249501518 creator A5073848858 @default.
• W2249501518 creator A5074457501 @default.
• W2249501518 date "2006-06-20" @default.
• W2249501518 modified "2023-09-25" @default.
• W2249501518 title "Implementation of 18F-FDG PET/CT in the management of colon cancer" @default.
• W2249501518 doi "https://doi.org/10.1200/jco.2006.24.18_suppl.13526" @default.
• W2249501518 hasPublicationYear "2006" @default.
• W2249501518 type Work @default.
• W2249501518 sameAs 2249501518 @default.
• W2249501518 citedByCount "0" @default.
• W2249501518 crossrefType "journal-article" @default.
• W2249501518 hasAuthorship W2249501518A5001407205 @default.
• W2249501518 hasAuthorship W2249501518A5010915843 @default.
• W2249501518 hasAuthorship W2249501518A5011192513 @default.
• W2249501518 hasAuthorship W2249501518A5021044941 @default.
• W2249501518 hasAuthorship W2249501518A5044706204 @default.
• W2249501518 hasAuthorship W2249501518A5059003996 @default.
• W2249501518 hasAuthorship W2249501518A5060807260 @default.
• W2249501518 hasAuthorship W2249501518A5073848858 @default.
• W2249501518 hasAuthorship W2249501518A5074457501 @default.
• W2249501518 hasConcept C121608353 @default.
• W2249501518 hasConcept C126322002 @default.
• W2249501518 hasConcept C126838900 @default.
• W2249501518 hasConcept C127077266 @default.
• W2249501518 hasConcept C2775842073 @default.
• W2249501518 hasConcept C2778357063 @default.
• W2249501518 hasConcept C2989005 @default.
• W2249501518 hasConcept C526805850 @default.
• W2249501518 hasConcept C71924100 @default.
• W2249501518 hasConceptScore W2249501518C121608353 @default.
• W2249501518 hasConceptScore W2249501518C126322002 @default.
• W2249501518 hasConceptScore W2249501518C126838900 @default.
• W2249501518 hasConceptScore W2249501518C127077266 @default.
• W2249501518 hasConceptScore W2249501518C2775842073 @default.
• W2249501518 hasConceptScore W2249501518C2778357063 @default.
• W2249501518 hasConceptScore W2249501518C2989005 @default.
• W2249501518 hasConceptScore W2249501518C526805850 @default.
• W2249501518 hasConceptScore W2249501518C71924100 @default.
• W2249501518 hasIssue "18_suppl" @default.
• W2249501518 hasLocation W22495015181 @default.
• W2249501518 hasOpenAccess W2249501518 @default.
• W2249501518 hasPrimaryLocation W22495015181 @default.
• W2249501518 hasRelatedWork W1541910640 @default.
• W2249501518 hasRelatedWork W183217539 @default.
• W2249501518 hasRelatedWork W1983237468 @default.
• W2249501518 hasRelatedWork W2004122934 @default.
• W2249501518 hasRelatedWork W2057903664 @default.
• W2249501518 hasRelatedWork W2070705913 @default.
• W2249501518 hasRelatedWork W2167718617 @default.
• W2249501518 hasRelatedWork W2731120814 @default.
• W2249501518 hasRelatedWork W2909852936 @default.
• W2249501518 hasRelatedWork W2951337402 @default.
• W2249501518 hasVolume "24" @default.
• W2249501518 isParatext "false" @default.
• W2249501518 isRetracted "false" @default.
• W2249501518 magId "2249501518" @default.
• W2249501518 workType "article" @default.